{"nctId":"NCT01068600","briefTitle":"Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks","startDateStruct":{"date":"2010-01"},"conditions":["Chronic Obstructive Pulmonary Disease"],"count":318,"armGroups":[{"label":"Indacaterol 75 µg","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo to indacaterol"]}],"interventions":[{"name":"Indacaterol","otherNames":[]},{"name":"Placebo to indacaterol","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of COPD (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2008) and:\n\n  1. Smoking history of at least 10 pack-years\n  2. Post-bronchodilator FEV1 \\<80% and ≥30% of the predicted normal value\n  3. Post-bronchodilator FEV1/FVC (forced vital capacity) \\<70%\n\nExclusion Criteria:\n\n* Patients who have had a COPD exacerbation requiring systemic corticosteroids and/or antibiotics and/or hospitalization for in the 6 weeks prior to screening\n* Patients who have had a respiratory tract infection within 6 weeks prior to screening\n* Patients with concomitant pulmonary disease\n* Patients with a history of asthma\n* Patients with diabetes Type I or uncontrolled diabetes Type II\n* Any patient with lung cancer or a history of lung cancer\n* Patients with a history of certain cardiovascular comorbid conditions\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment","description":"Spirometry was conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 hour 10 minute and 23 hour 45 minute post-dose FEV1 readings. Mixed model used baseline FEV1, FEV1 prior to and 10-15 minutes post inhalation of albuterol, and FEV1 prior to and 50-70 minutes post inhalation of ipratropium as covariates.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.49","spread":"0.016"},{"groupId":"OG001","value":"1.35","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"Transition Dyspnoea Index (TDI) Focal Score After 12 Weeks of Treatment","description":"TDI focal score is based on three domains: functional impairment, magnitude of task and magnitude of effort. Each domain is scored from -3 (major deterioration) to 3 (major improvement) to give an overall TDI focal score of -9 to 9 with a negative score indicating a deterioration from baseline. A 1 unit difference in the TDI focal score is clinically significant. Mixed model used baseline dyspnoea index, FEV1 prior to and 10-15 minutes post inhalation of albuterol, and FEV1 prior to and 50-70 minutes post inhalation of ipratropium as covariates.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.22","spread":"0.234"},{"groupId":"OG001","value":"0.76","spread":"0.235"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":159},"commonTop":["Chronic obstructive pulmonary disease","Cough","Nasopharyngitis","Upper respiratory tract infection","Oropharyngeal pain"]}}}